Jose Antonio Perdomo

Publication List Details

Period

1985 - 2007

Number

7

Co-Authors

Surgical treatment for Crohn's disease. (2007)

Perdomo, Jose Antonio, Iwagaki, Hiromi, Hizuta, Akio, Mizuno, Motowo, Nakagawa, Hitoshi, Tanaka, Noriaki, ...

The medical records of 16 consecutive patients with Crohn's disease surgically treated in our department from 1978 to 1993 were retrospectively reviewed. The indication for surgery was obstructive...

The importance of family study in the patients with familial adenomatous polyposis. (2007)

Perdomo, Jose Antonio, Iwagaki, Hiromi, Hizuta, Akio, Tanaka, Noriaki, Orita, Kunzo

Familial adenomatous polyposis (FAP) is a well-known autosomal dominant disorder characterized by the formation of multiple adenomatous polyps of the colon. Gardner's syndrome is a variant of...

Clinical value of soluble interleukin-2 receptor in infectious complications. (2007)

Iwagaki, Hiromi, Hizuta, Akio, Iwadou, Hironori, Perdomo, Jose Antonio, Tanaka, Noriaki, Orita, Kunzo

In this study, we investigated serum-soluble interleukin-2 receptor (sIL-2r) and neopterin (NPT) levels in five patients with severe postoperative infections. A total of 25 synchronous determinations...

Endoscopical Segmental Piecemeal Tumorectomy for Nodular Elevation of Colorectal Tumor: Applicability and Patient's Quality of Life (2007)

Ariki, Norifumi, Iwagaki, Hiromi, Yoshino, Tadashi, Nonaka, Yasuyuki, Fujiki, Shigeatsu, Perdomo, Jose Antonio, ...

Endoscopical segmental piecemeal tumorectomy (ESPT) for nodular elevation of colorectal tumor is advantageous in terms of minimizing both surgical invasion and postoperative burden to the patients....

Effect of low dose cyclophosphamide on the synthesis of acute phase protein and its significance for cancer chemotherapy. (2007)

Iwagaki, Hiromi, Hizuta, Akio, Fujiwara, Toshiyushi, Perdomo, Jose Antonio, Tanaka, Noriaki, Orita, Kunzo

Patients with far advanced colorectal cancers received chemotherapy consisting of low-dose cyclophosphamide (LDCY) 333 mg/m2 every four weeks intravenously and by oral administration of 5'-DFUR (a...